Skipping $2m EBITDA Deals ("The Messy Middle")
Dan Tamkin of Resurgent Capital Partners shares his barbell strategy for lower-middle market PE deals, avoiding the "messy middle" to maximize returns.
Dan Tamkin, based in California and co-founder of Resurgent Capital Partners, is an operator, technologist, and turnaround investor, in that order. After a career revolving around tech turnarounds and challenged VC portcos, he has found the lower-middle market to be a better channel for value creation, especially when done via the deal-by-deal model of independent sponsorship.
Resurgent began in 2017 and now has a portfolio of 6 platforms, split 3 vs. 3 between larger deals that required external equity and smaller companies they could buy outright. They follow a barbell strategy: concentrate on very small deals (~$0.5m EBITDA) that they can control and on larger deals ($5m+ EBITDA) where the upside is meaningful, while avoiding the middle, while skipping the $2-4m EBITDA range. Their underwriting targets an "acceptable return" by keeping stable and/or fixing 1–2 core issues, then views "explosive return" as a potential that can materialy if one or more growth levers are realized.
They built Resurgent through bootstrapping. Dan had a consulting turnaround job that generated revenue which seeded Resurgent. His partner, Bryce, used that runway to source deals, travel, and acquire a small cash-flowing asset. This early holding created a track record and stable income.
Dan warns repeatedly about the $2m EBITDA case study, which he calls "the messy middle." Here's his math: Buy at 5x ($10m EV), double EBITDA to $4m over 5 years, and exit at 5x again ($20m EV). After 20 percent carry, fees, and taxes, the sponsor duo might net only ~$500k per partner for years of work.
He contrasts the lower-middle market PE with venture capital. In VC, boards are composed of fund investors who have different fund timeline, portfolio pressures, and motivations, all of which skews and delays decision-making. The lower-middle market offers a dynamic with stable businesses under clear ownership, a couple of discrete, endogenous* fixable problems, and achievable value creation without relying on optimism about market dominance.
More recent episodes
The Doctor & The Finance Bro
Dr. Lisa Piercey’s path spans pediatric medicine, hospital leadership, Tennessee Health Commissioner and now independent sponsor nearing her fifth healthcare platform. Her edge: deep operating and policy expertise across reimbursement, Medicaid, aging and value-based care.
$2M to Start as an IndependentSponsor
Drew Bagin and his partner raised $2m in GP seed capital before their first independent sponsor deal. Five platforms later, their New England focus has created a differentiated sourcing and value-creation network, with a fire protection platform nearing exit.
Behind The Scenes: Our Unique Angle In An Increasingly Crowded Space
The 3 founding partners mark the 75th episode with a behind-the-scenes look at their strategy, discussing rollup frequency, first-time sponsor pitfalls, AI in underwriting and capital supply-demand imbalances across the independent sponsor ecosystem.